Preferred Label : Receptors, Chimeric Antigen;
MeSH definition : Synthetic cellular receptors that reprogram T-LYMPHOCYTES to selectively bind antigens.;
MeSH synonym : Antigen Receptors, Chimeric; Artificial T-Cell Receptors; Artificial T Cell Receptors; Receptors, Artificial T-Cell; T-Cell Receptors, Artificial; Chimeric T-Cell Receptors; Chimeric T Cell Receptors; Receptors, Chimeric T-Cell; T-Cell Receptors, Chimeric; Chimeric Antigen Receptors; Chimeric Immunoreceptors; Immunoreceptors, Chimeric; Chimeric Antigen Receptor; Antigen Receptor, Chimeric; Receptor, Chimeric Antigen; Chimeric T-Cell Receptor; Chimeric T Cell Receptor; Receptor, Chimeric T-Cell; T-Cell Receptor, Chimeric;
MeSH annotation : for CAR-T Cell Therapy, coordinate with CHIMERIC ANTIGEN RECEPTOR THERAPY see IMMUNOTHERAPY,
ADOPTIVE;
Origin ID : D000076962;
UMLS CUI : C4039583;
Allowable qualifiers
Automatic exact mappings (from CISMeF team)
Record concept(s)
Related MeSH Supplementary Concept(s)
See also
Semantic type(s)
UMLS correspondences (same concept)
Synthetic cellular receptors that reprogram T-LYMPHOCYTES to selectively bind antigens.
https://ansm.sante.fr/tableau-marr/ciltacabtagene-autoleucel
2023
false
false
false
France
French
risk management
guidelines for drug use
patient education handout
Ciltacabtagene Autoleucel
infusions, intravenous
immunotherapy, adoptive
Product containing genetically modified T-cell (product)
Receptors, Chimeric Antigen
Cytokine Release Syndrome
continuity of patient care
Ciltacabtagene Autoleucel
neurotoxicity syndromes
drug compounding
ciltacabtagene autoleucel
---
https://www.ema.europa.eu/en/medicines/human/EPAR/abecma
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
Idecabtagene Vicleucel
Idecabtagene Vicleucel
Receptors, Chimeric Antigen
Receptors, Chimeric Antigen
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
gene therapy
orphan drug production
multiple myeloma
adult
Refractory Multiple Myeloma
recurrence
infusions, intravenous
continuity of patient care
Cytokine Release Syndrome
Drug-Related side effects and adverse reactions
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Triple-Class Refractory Multiple Myeloma
idecabtagene vicleucel
idecabtagene vicleucel
---
https://www.has-sante.fr/jcms/p_3303102/fr/abecma-idecabtagene-vicleucel-myelome-multiple
https://has-sante.fr/jcms/p_3303143/fr/decision-n-2021-0311/dc/sem-du-2-decembre-2021-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-abecma-idecabtagene-vicleucel
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
Idecabtagene Vicleucel
Idecabtagene Vicleucel
Receptors, Chimeric Antigen
immunotherapy, adoptive
adult
recurrence
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
infusions, intravenous
Triple-Class Refractory Multiple Myeloma
idecabtagene vicleucel
idecabtagene vicleucel
evaluation of the transparency committee
multiple myeloma
---